Brief: Relmada Therapeutics Provides Corporate Update And Reports Third Quarter 2022 Financial Results
10/11/2022 22:05
Nov 10 (Reuters) - Relmada Therapeutics Inc RLMD.O :
* RELMADA THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS
THIRD
QUARTER 2022 FINANCIAL RESULTS
* NET LOSS FOR THREE MONTHS ENDED SEPTEMBER 30, 2022, WAS
$39.4
MILLION, OR $1.31 PER DILUTED SHARE
* Q3 EARNINGS PER SHARE VIEW $-1.45 -- REFINITIV IBES DATA
Source text for Eikon: ID:nPn4DJrzva
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million